This technique was also reported to distinguish pancreatic cancer patients from healthy subjects via detection of an EV marker, ephrin type-A receptor 2 (EphA2), associated with pancreatic cancer for clinical diagnosis and prognosis (Liang et al., 2017a). This evidence concerns the gene EPHA2 and pancreatic neoplasm.